Browsing Tag
Exelixis Inc.
1 post
Handa Pharmaceuticals wins final FDA approval for OMCAZIO as $2.1bn Cabometyx market faces new rival
Handa Pharmaceuticals has secured final FDA approval for OMCAZIO, a cabozantinib formulation that can be taken with or without food, opening U.S. competition around Exelixis’ multibillion-dollar franchise.